Johnson & Johnson has confirmed an agreement to fork over at least $2.5 billion to settle thousands of lawsuits alleging injuries caused by defective all-metal hip implants. A large majority of eligible plaintiffs reportedly must support the agreement for it to go forward, and legions of legal cases not included in the deal will remain in play.
With more than 10,000 lawsuits already in the mix, Johnson & Johnson must deal with yet another patient's allegation's that company knowingly sold faulty metal hip implants and didn't warn the public.
Johnson & Johnson has had enough with metal-on-metal and ceramic-on-metal hips, disclosing that it will leave those business lines entirely behind by the end of 2014.
After losing two jury trials, Johnson & Johnson/DePuy can now celebrate the fact that a jury has ruled in its favor regarding the company's ASR all metal hip implant.
Johnson & Johnson's $8.3 million defeat in a U.S. jury trial over its ASR metal-on-metal hip implant could force it to settle a massive class action lawsuit in Australia over the same product.
As if 8,000-plus lawsuits alleging faulty all metal helps weren't enough, Johnson & Johnson/DePuy data from an Illinois hospital suggests that repeat surgeries for patients dealing with the implants keep rising.
A Johnson & Johnson executive testified that the company recalled its all-metal hip replacements because they didn't meet "clinical expectations," not because they were defective, but that doesn't quite jibe with internal documents.
When Johnson & Johnson's metal-on-metal hip implants failed an internal safety test, the company opted against fixing the issue and instead just changed its protocols, a witness testified in one of thousands of lawsuits the drug and device giant now faces.
Johnson & Johnson was aware of the alarming failure rates of ASR hip implants a year before the company stopped making them and two years before they were recalled.
Three plaintiffs settled their lawsuits against Johnson & Johnson ($JNJ)/DePuy over health problems they say stemmed from the failure of the company's metal-on-metal hip implants.